Security
PMV Pharmaceuticals, Inc. Common Stock · PMVP
PMVPNASDAQCommon stockCurrentCIK 1699382Updated Oct 6, 2026
PMVP price & chart
Loading TradingView…
NASDAQ:PMVP on TradingView ↗About the company
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53. TP53 mutations are found in approximately half of all cancers. Our co-founder, Dr. Arnold Levine, established the field of p53 biology when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize more than four decades of p53 biology, PMV Pharma combines unique biological understanding with a pharmaceutical development focus. PMV Pharma is headquartered in Princeton, New Jersey. For more information, please visit www.pmvpharma.com.
In the news
PMV Pharma Announces Proposed Public Offering of Securities ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
SCHEDULE 13G - filed by Samsara BioCapital, L.P. regarding PMV Pharmaceuticals, Inc.
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
424B3 filing
Show 5 more recent filings
424B5 filing
Other Events
Items 8.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 116,562,000Source | 191,288,000Source | 252,152,000Source | 270,308,000Source |
| Property, Plant and Equipment, NetUSD | 237,000Source | 409,000Source | 10,666,000Source | 10,955,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 37,983,000Source | 40,876,000Source | 37,706,000Source | 108,297,000Source |
| Assets, CurrentUSD | 115,227,000Source | 175,658,000Source | 207,409,000Source | 247,006,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,284,000Source | 6,204,000Source | 3,530,000Source | 5,130,000Source |
| Operating Lease, Right-of-Use AssetUSD | 801,000Source | 1,143,000Source | 8,382,000Source | 9,539,000Source |
| Other Assets, NoncurrentUSD | 297,000Source | 235,000Source | 190,000Source | 313,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 11,850,000Source | 15,208,000Source | 26,463,000Source | 24,280,000Source |
| Stockholders’ equity: | ||||
| Retained Earnings (Accumulated Deficit)USD | -446,454,000Source | -368,712,000Source | -310,003,000Source | -241,043,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 84,000Source | 139,000Source | 224,000Source | -445,000Source |
| Stockholders' Equity Attributable to ParentUSD | 104,712,000Source | 176,080,000Source | 225,689,000Source | 246,028,000Source |
| Additional Paid in Capital, Common StockUSD | 551,082,000Source | 544,653,000Source | 535,468,000Source | 487,516,000Source |
| Liabilities and EquityUSD | 116,562,000Source | 191,288,000Source | 252,152,000Source | 270,308,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,415,000Source | 14,370,000Source | 14,029,000Source | 10,832,000Source |
| Operating Lease, Liability, CurrentUSD | 403,000Source | 352,000Source | 852,000Source | 528,000Source |
| Accounts Payable, CurrentUSD | 3,155,000Source | 6,579,000Source | 3,237,000Source | 2,996,000Source |
| Operating Lease, Liability, NoncurrentUSD | 435,000Source | 838,000Source | 12,434,000Source | 13,448,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 7,857,000Source | 7,439,000Source | 9,940,000Source | 7,308,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 112,943,000Source | 183,297,000Source | 228,562,000Source | 243,549,000Source |
| Deferred Tax Liabilities, NetUSD | 265,000Source | 369,000Source | 2,576,000Source | 2,738,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -77,742,000Source | -58,709,000Source | -68,960,000Source | -73,317,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 5,924,000Source | 8,872,000Source | 12,375,000Source | 10,195,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -3,424,000Source | 3,342,000Source | 235,000Source | -389,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -73,577,000Source | -51,282,000Source | -55,657,000Source | -63,760,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 70,172,000Source | 53,352,000Source | -50,545,000Source | -1,368,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 29,000Source | 655,000Source | 962,000Source | 7,984,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 505,000Source | 313,000Source | 35,577,000Source | 958,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -2,893,000Source | 2,348,000Source | -70,591,000Source | -64,170,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 5,924,000Source | 8,872,000Source | 12,375,000Source | 10,195,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 112,943,000Source | 183,297,000Source | 228,562,000Source | 243,549,000Source |
| DepreciationUSD | 133,000Source | 1,144,000Source | 1,257,000Source | 315,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -37,000Source | -62,000Source | — | — |
| Gain (Loss) on Termination of LeaseUSD | — | -4,604,000Source | — | — |
| General and Administrative ExpenseUSD | 16,329,000Source | 26,921,000Source | 24,247,000Source | 25,052,000Source |
| Income Tax Expense (Benefit)USD | -2,172,000Source | -16,100,000Source | 2,000Source | -9,000Source |
| Net Income (Loss) Attributable to ParentUSD | -77,742,000Source | -58,709,000Source | -68,960,000Source | -73,317,000Source |
| Operating ExpensesUSD | 86,206,000Source | 85,448,000Source | 80,132,000Source | 77,040,000Source |
| Operating Lease, ExpenseUSD | 471,000Source | 1,194,000Source | 1,913,000Source | 2,215,000Source |
| Other Nonoperating Income (Expense)USD | 6,292,000Source | 10,639,000Source | 11,174,000Source | 3,714,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 35,121,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 958,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -86,206,000Source | -85,448,000Source | -80,132,000Source | -77,040,000Source |
| Other Nonoperating Income (Expense)USD | 6,292,000Source | 10,639,000Source | 11,174,000Source | 3,714,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -79,914,000Source | -74,809,000Source | -68,958,000Source | -73,326,000Source |
| Income Tax Expense (Benefit)USD | -2,172,000Source | -16,100,000Source | 2,000Source | -9,000Source |
| Net Income (Loss) Attributable to ParentUSD | -77,742,000Source | -58,709,000Source | -68,960,000Source | -73,317,000Source |
| Earnings Per Share, BasicUSD per share | -1.48Source | -1.14Source | -1.44Source | -1.61Source |
| Earnings Per Share, DilutedUSD per share | -1.48Source | -1.14Source | -1.44Source | -1.61Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 52,541,613Source | 51,578,807Source | 48,014,645Source | 45,594,824Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 52,541,613Source | 51,578,807Source | 48,014,645Source | 45,594,824Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 16,329,000Source | 26,921,000Source | 24,247,000Source | 25,052,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -79,937,000Source | — | — | — |
| Interest Income (Expense), NetUSD | 6,337,000Source | 10,655,000Source | 11,171,000Source | 3,627,000Source |
| Operating ExpensesUSD | 86,206,000Source | 85,448,000Source | 80,132,000Source | 77,040,000Source |
| Operating Lease, ExpenseUSD | 471,000Source | 1,194,000Source | 1,913,000Source | 2,215,000Source |
| Research and Development ExpenseUSD | 69,877,000Source | 58,527,000Source | 55,885,000Source | 51,988,000Source |
Filing attachments
d174662dex991.htm · 8-K · 2026-10-05
Exhibit 99.1 PMV Pharmaceuticals Appoints Matt Eckler, Ph. D., to Board of Directors Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., October 5, 2026 (GLOBE NEWSWIRE) - PMV P…
Read attachment ↗d113784dex41.htm · 8-K · 2026-09-02
EX-4.1 3 d113784dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PMV PHARMACEUTICALS, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: September [ ], 2026 ───────────────────────────────────────────────────────────────── PMV Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowl…
Read attachment ↗d113784dex42.htm · 8-K · 2026-09-02
EX-4.2 4 d113784dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 PMV PHARMACEUTICALS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: September [ ], 2026 ───────────────────────────────────────────────────────────────── PMV Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are he…
Read attachment ↗d113784dex991.htm · 8-K · 2026-09-02
EX-99.1 6 d113784dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PMV Pharma Announces Pricing of Oversubscribed $50Million Public Offering of Securities PRINCETON, N.J., August 31, 2026 (GLOBE NEWSWIRE) - PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its comm…
Read attachment ↗d441751dex991.htm · 8-K · 2026-08-31
EX-99.1 2 d441751dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial 46% ORR observed among 76 evaluable patients in the ovarian cancer cohort with a median duration of response of 10.0 months Recent FDA interaction supports NDA submission strategy for accelerated approval of rezatapopt for platinum-resistant/refractory ovarian cancer, with submission planned…
Read attachment ↗pmvp-ex99_1.htm · 8-K · 2026-08-14
EX-99.1 2 pmvp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed • Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 • Cash, cash equivalents, and marketable securities of $79.4 mil…
Read attachment ↗